Remarkably, this dependency on GPX4 and sensitivity to ferroptosis is shared broadly across a wide range of cancer types and different treatment regimens suggesting this pathway may represent a general liability of drug tolerant cell populations that may offer therapeutic opportunities to prevent acquired therapy resistance. This evidence concerns the gene GPX4 and cancer.